SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing S... (n adverse drug reaction reported from cl...)

HOME >> MEDICINE >> TECHNOLOGY

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Date:6/26/2009

n adverse drug reaction reported from clinical trials through week 16 was upper respiratory tract infection (7.2 percent of SIMPONI-treated patients compared with 5.8 percent in control-treated patients). In controlled Phase 3 trials through Week 16 in RA, PsA and AS, 5.8 percent of SIMPONI treated patients had injection site reactions compared with 2.2 percent in control-treated patients. The majority of the injection site reactions were mild and moderate, and the most frequent manifestation was injection site erythema.

For the Full U.S. Prescribing Information and Medication Guide, please visit www.SIMPONI.com.

About Centocor Ortho Biotech, Inc.

Centocor Ortho Biotech Inc. redefines the standard of care in immunology, nephrology, and oncology. The company was created when Ortho Biotech Inc. merged into Centocor, Inc., and Centocor, Inc. was renamed Centocor Ortho Biotech Inc. Built upon a pioneering history, Centocor Ortho Biotech Inc. harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates, and healthcare professionals have access to the latest treatment information, support services, and quality care. Centocor Ortho Biotech is a wholly-owned subsidiary of Johnson & Johnson.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Centocor Ortho Biotech Inc. and/or Johnson & Johnso
'/>"/>

SOURCE Schering-Plough Corporation; Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
2. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
3. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
4. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
5. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
6. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
7. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
8. AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
9. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
10. Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma
11. Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles

Post Your Comments:

(Date:12/14/2009)... Dec. 14 Cardium Therapeutics (NYSE Amex: ... 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment ... Healing: Science and Industry Conference held December 10-13, ... The conference is attended by top industry leaders ... wound healing. Dr. Barbara K. Sosnowski, Cardium,s ...

(Date:12/14/2009)... SKIPPACK, Pa., Dec. 14 At GeoInvesting.com, we ... ) for some time now. Our largest hang up ... Although the Company,s fiscal June 2010 net income guidance ... fiscal 2009 reported net income of $7.9 million, the ... term EPS growth scenario, which depends upon the share ...

(Date:12/14/2009)... HELSINKI, Dec. 14 Cancer patients in ... with the introduction of RapidArc® radiotherapy technology from ... at the only private radiotherapy clinic in the ... are using this fast and precise form of ... and cancers of the abdomen and prostate. ,, ...

Breaking Medicine Technology:Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 2 Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 3 Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 4 GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms 2 Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2 Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3 Time to Turn the Town Pink 57587 1 Time to Turn the Town Pink 57587 2 Dey L P Settles State of Utah Pricing Litigation 57583 1 Dey L P Settles State of Utah Pricing Litigation 57583 2 The Lustgarten Foundation Expresses Condolences as Pancreatic Cancer Claims Life of Myles Brand 57580 1

[0] Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development [0] GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms [0] Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments

... - ORENCIA is a First-in-Class Biologic Treatment Option Now Available ... Use in Pediatric Patients with ... Company (NYSE: BMY ) today announced that the U.S. ... signs,and symptoms in pediatric patients six years and older with ...

... Inc. (Nasdaq: ARNA ) announced today that ... of APD125 in patients with primary,insomnia. APD125 is ... the,potential to reduce insomnia symptoms and improve sleep ... APD125 is a double-blind, randomized, placebo-,controlled subjective study ...

U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia

(Date:12/15/2009)... bill Medicare for consultations how will they get paid for ... to understand terms. , ... Washington, ... Medicare will eliminate consultation codes. These codes are what ... is seen for a medical consultation, whether in a provider’s ...

(Date:12/15/2009)... America,s premier manufacturer of Spa, Massage, and Medical tables announces ... an adjustable breast comfort system to ease pressure felt while ... ... New Freedom, Pennsylvania (PRWEB) December 15, 2009 -- OAKWORKS®, ... equipment, today announced the launch of the Utopian Massage Table ...

(Date:12/15/2009)... 15 issue of the Journal of Clinical Sleep ... the risk for developing obstructive sleep apnea (OSA) in ... Results indicate that the risk of OSA among Caucasian ... fold with each standard-deviation increase in body mass index ... significantly increase with increasing BMI among younger children. ...

(Date:12/14/2009)... and synthetic red-blood-cell-like particles carry oxygen, drugs, and more… ... ... Scientists at UC Santa Barbara, in collaboration with scientists at ... the characteristics and key functions of natural red blood cells, ... , , , , ,The primary function of natural red ...

(Date:12/14/2009)... LOVELAND, Colo., Dec. 14 Heska ... the "Company"), a leading provider of veterinary ... first customer installation of the Company,s new ... 7000"). ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ) ,, ... the fastest multi-patient clinical chemistry analyzer available ...

Breaking Medicine News(10 mins):Health News:Medicare Eliminates Consultation Codes for Doctors 2 Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 2 Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 3 Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 4 Health News:Obesity increases the risk for obstructive sleep apnea in adolescents, but not in younger children 2 Health News:Synthetic Red Blood Cells Developed 2 Health News:Synthetic Red Blood Cells Developed 3 Health News:Heska Announces Installation of New Chemistry Analyzer 2 Health News:Heska Announces Installation of New Chemistry Analyzer 3

[0] Medicare Eliminates Consultation Codes for Doctors [0] Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table [1] Obesity increases the risk for obstructive sleep apnea in adolescents, but not in younger children [0] Synthetic Red Blood Cells Developed [0] Heska Announces Installation of New Chemistry Analyzer

... displacement in the ivyleaf morning glory" , Robin ... , How do we know that interactions between ... abundant evidence to suggest that plant-pollinator interactions influence ... direct evidence that interactions between plant species shape ...

... INDIANAPOLIS, Jan. 4 Eli Lilly and Company,(NYSE: LLY ... and,full year of 2007 on Tuesday, January 29, 2008. Lilly ... investment community and media to,further detail the company,s financial performance., ... to 10:00 a.m. EST.,Investors, media and the general public can ...

... HARRISBURG, Pa., Jan. 4 With the cut of ... some 400 jobs in,Northumberland County and mark the acquisition ... PRWT Services Inc. took over the operation of ... Danville, on Jan. 1. The facility will be,known as ...

... as well with more cost-effective conventional film screenings, study ... results from a landmark trial released in 2005 concluded ... cancers than conventional film mammography was. , But a ... of Internal Medicine , concludes that digital mammography is ...

... get serious about ... health, once and for all, NEW ... and stroke are the nation,s No. 1 and No. 3,killers, claiming ... obese., (Photo: http://www.newscom.com/cgi-bin/prnh/20080104/LAF034 ), World-renowned entertainer Donny Osmond ...

... for 29 categories of awards in the 2007 Association ... Best Monthly Professional Society Magazine as well as the ... winners will be honored at the Salute to Association ... 1996, JBS is the official publication of the Society ...

January American Naturalist highlights Lilly Sets Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results Announcement Governor Rendell Lauds 'Rebirth' of Drug Manufacturing Plant in Danville Area Not All Women Need Digital Mammograms Donny Osmond, American Heart Association Team Up to Get Americans Walking The Journal of Biomolecular Screening garners Association TRENDS Bronze Award

... The StatSpin CytoFuge 2 is the ... It's simple, understandable controls and new snap-seal ... before. Samples are processed quickly, silently and ... safety cabinet. Results are consistent: easy to ...

Unique "finger-stick" collection system utilizes a capillary tube for easy blood drawing; no "scooping" necessary. After draining into a microtube, blood is centrifuged and serum or plasma is easily ...

... improved safety and lower cost per test for ... sample prep bottlenecks in the busy clinical lab... ... and quiet centrifuge spins standard 5 mL blood ... produces quality serum or plasma equal to 10-15 ...

Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...

Medicine Products:

CytoFuge 2 StatSampler StatSpin Express 2 Silicone Foley

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing S...(n adverse drug reaction reported from cl...),Health